Business EconomyPosted at: Jan 23 2026 11:38PM

Hyderabad, Jan 23 (UNI) Granules India Ltd on Friday reported a strong set of numbers for the third quarter ended December 31, 2025, led by robust demand in its finished dosages business in key global markets.
Profit before tax (PBT) stood at ₹2,022 million, up 32 percent YoY, while profit after tax (PAT) grew 28 percent to ₹1,502 million during the quarter, the Hyderabad-based pharmaceutical company said in a release here.
Revenue from operations rose 22 per cent year-on-year to ₹13,879 million, compared with ₹11,377 million in the corresponding quarter last year.
EBITDA increased 34 per cent YoY to ₹3,081 million, with margins expanding to 22 percent from 20 percent a year ago.
Growth was primarily driven by the company’s finished dosages (FD) segment, particularly in North America and Europe.
During Q3 FY26, finished dosages accounted for 76 percent of total revenue, while active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI) contributed 11 percent each.
The peptides/CDMO business made up the remaining 2 percent.
The company’s return on capital employed (ROCE) improved to 16.8 percent, compared with 16.4 per cent a year earlier, post the acquisition of Senn Chemicals AG. Net debt stood at ₹10,151 million, with a net debt-to-EBITDA ratio of 0.91x, reflecting a healthy balance sheet.
Commenting on the performance, Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, said the quarter was among the company’s strongest, driven by disciplined execution of growth initiatives, continued R&D investments, expansion of the global supply footprint and progress in ESG initiatives.
UNI KNR RN

Please log in to get detailed story.